Early Cancer Detection

Personalis, Inc. (PSNL) stands out as an attractive investment opportunity thanks to its flagship NeXT Personal test, a liquid‑biopsy platform that identifies cancer recurrence 12–18 months earlier than conventional imaging. The assay employs whole‑genome sequencing to track up to 1,800 tumor variants, yielding significantly higher detection rates than competitors such as Natera’s Signatera. Although NeXT Personal presently contributes less than 1 % of PSNL’s $85 M revenue, the test has already secured a user base of over 600 oncologists and boasts a 98 % retention rate.